Selinexor Treatment of Refractory Myeloma
Public ClinicalTrials.gov record NCT02336815. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM (Part 1 only).
Study identification
- NCT ID
- NCT02336815
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 202 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 26, 2015 (Actual)
- Primary completion
- Jul 26, 2019 (Actual)
- Completion
- Jul 26, 2019 (Actual)
- Last update posted
- Jan 26, 2023
2015 – 2019
United States locations
- U.S. sites
- 36
- U.S. states
- 25
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35294 | — |
| Mayo Clinic (AZ) | Scottsdale | Arizona | 85259 | — |
| City of Hope | Duarte | California | 91010 | — |
| Jonnsson Comprehensive Cancer Center / University of Los Angeles | Los Angeles | California | 90095 | — |
| Smilow Cancer Hospital | New Haven | Connecticut | 06510 | — |
| University of Florida Health Cancer Center- Shands Cancer Center Hospital | Gainesville | Florida | 32608 | — |
| Sylvester, University of Miami | Miami | Florida | 33136 | — |
| H. Lee Moffitt Cancer Center Research Institute | Tampa | Florida | 33612 | — |
| Emory University / Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Northside Hospital | Atlanta | Georgia | 30342 | — |
| Kaiser Permanente- Hawaii | Honolulu | Hawaii | 96819 | — |
| University of Chicago Medicine | Chicago | Illinois | 60637 | — |
| Indiana University Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| University of Iowa Hospitals & Clinics | Iowa City | Iowa | 52242 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| Johns Hopkins Medicine | Baltimore | Maryland | 21287 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute / Wayne State University | Detroit | Michigan | 48201 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Washington University St. Louis | St Louis | Missouri | 63110 | — |
| Hackensack University Medical Center / John Therurer Cancer Center | Hackensack | New Jersey | 07601 | — |
| Valley Hospital | Paramus | New Jersey | 07652 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14203 | — |
| NYU Perlmutter Cancer Center | New York | New York | 10016 | — |
| Mt Sinai NYC | New York | New York | 10029 | — |
| Columbia University | New York | New York | 10032 | — |
| UNC-Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Kaiser Permanente Northwest OR | Portland | Oregon | — | — |
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Vanderbilt University Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| Baylor Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Swedish Cancer Institute | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02336815, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 26, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02336815 live on ClinicalTrials.gov.